A novel antimetabolite: TAS-102 for metastatic colorectal cancer

References

• Torre LA, Bray F, Siegel RL, et. al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Manfredi S, Lepage C, Hatem C, et. al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–259.
   PubMed Web of Science ®Google Scholar
• Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82:114–129.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et. al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl(6):vi64–72.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Itabashi M, Shimada Y, et. al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–239.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Dannberg P, et. al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass HO, Jr, Herrera L, et. al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. gastrointestinal tumor study group. J Clin Oncol. 1989;7:1419–1426.
   PubMed Web of Science ®Google Scholar
• Poon MA, O’Connell MJ, Wieand HS, et. al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9:1967–1972.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Bosset JF, Milan C, et. al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–815.
   PubMed Web of Science ®Google Scholar
• Kohne CH, Wils J, Lorenz M, et. al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of research and treatment of cancer gastrointestinal group study 40952. J Clin Oncol. 2003;21:3721–3728.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et. al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343:905–914.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M, et. al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et. al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et. al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et. al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et. al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, et. al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz H-J, Kohne C-H, et. al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692–700.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Siena S, Cassidy J, et. al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–4705.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Oliner KS, Siena S, et. al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–1034.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et. al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et. al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et. al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Niedzwiecki D, Innocenti F, et. al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol. 2014;25(Suppl. 4):A5010.
   Google Scholar
• Loupakis F, Cremolini C, Masi G, et. al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takahari D, Matsumoto H, et. al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–1286.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Nagase M, Tamagawa H, et. al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan oncology group study 4407G (WJOG4407G). J Clin Oncol. 2014;32(5s):suppl; abstr 3534.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Parsons DG, Remy DC, Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2ʹ-deoxyuridine. J Med Chem. 1964;7:1–5.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, King DH. Trifluorothymidine. Pharmacol Ther. 1979;6:427–442.
   Web of Science ®Google Scholar
• Heidelberger C, Boohar J, Kampschroer B. Fluorinated pyrimidines. XXIV. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2ʹ-deoxyuridine-2-14. Cancer Res. 1965;25:377–381.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Honeywell R, Leon L, et. al. Role of pharmacodynamic, pharmacogenetic and pharmacogenomic biomarkers of cancer chemotherapy with antifolates. Pteridines. 2009;20:s115–127.
   Web of Science ®Google Scholar
• Temmink OH, Emura T, De Bruin M, et. al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779–789.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Sakamoto K, Okabe H, et. al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32:2319–2326.
   PubMed Web of Science ®Google Scholar
• Temmink OH, Comijn EM, Fukushima M, et. al. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleos Nucleot Nucl Acids. 2004;23:1491–1494.
   PubMed Web of Science ®Google Scholar
• Temmink OH, De Bruin M, Comijn EM, et. al. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs. 2005;16:285–292.
   PubMed Web of Science ®Google Scholar
• Emura T, Murakami Y, Nakagawa F, et. al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13:545–549.
   PubMed Web of Science ®Google Scholar
• Emura T, Suzuki N, Yamaguchi M, et. al. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25:571–578.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Iimori M, Niimi S, et. al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14:1004–1013.
   PubMed Web of Science ®Google Scholar
• Matulic-Adamic J, Takahashi K, Chou TC, et. al. Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2ʹ-deoxyuridine and 2ʹ-deoxy-2ʹ-fluoro-beta-D-arabinofuranosyluracil. J Med Chem. 1988;31:1642–1647.
   PubMed Web of Science ®Google Scholar
• Emura T, Nakagawa F, Fujioka A, et. al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med. 2004;13:249–255.
   PubMed Web of Science ®Google Scholar
• Utsugi T. New challenges and inspired answers for anticancer drug discovery and development. Jpn J Clin Oncol. 2013;43:945–953.
   PubMed Web of Science ®Google Scholar
• Dexter DL, Wolberg WH, Ansfield FJ, et. al. The clinical pharmacology of 5-trifluoromethyl-2ʹ-deoxyuridine. Cancer Res. 1972;32:247–253.
   PubMed Web of Science ®Google Scholar
• Emura T, Suzuki N, Fujioka A, et. al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol. 2005;27:449–455.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Suzuki N, Emura T, et. al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2ʹ-deoxyribonucleosides. Biochem Pharmacol. 2000;59:1227–1236.
   PubMed Web of Science ®Google Scholar
• Mimori K, Matsuyama A, Yoshinaga K, et. al. Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology. 2002;62:327–332.
   PubMed Web of Science ®Google Scholar
• El Kouni MH, El Kouni MM, Naguib FN. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res. 1993;53:3687–3693.
   PubMed Web of Science ®Google Scholar
• Maehara Y, Nakamura H, Nakane Y, et. al. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gan. 1982;73:289–298.
   PubMedGoogle Scholar
• Takebayashi Y, Yamada K, Miyadera K, et. al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer. 1996;32A:1227–1232.
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang HT, Fan TP, et. al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A. 1995;92:998–1002.
   PubMed Web of Science ®Google Scholar
• Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem. 2003;278:19272–19279.
   PubMed Web of Science ®Google Scholar
• De Bruin M, Van Capel T, Van Der Born K, et. al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer. 2003;88:957–964.
   PubMed Web of Science ®Google Scholar
• Matsushita S, Nitanda T, Furukawa T, et. al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999;59:1911–1916.
   PubMed Web of Science ®Google Scholar
• Brown NS, Jones A, Fujiyama C, et. al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000;60:6298–6302.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ellis LM, Mai M. The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep. 2003;10:9–13.
   PubMed Web of Science ®Google Scholar
• Amaya H, Tanigawa N, Lu C, et. al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119:227–235.
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Yoshino T, et. al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107:429–434.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yoshisue K, Chiba M, et. al. Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluridine using human small intestinal epithelial cells. J Pharm Sci. 2015;104:3146–3153.
   PubMed Web of Science ®Google Scholar
• Pouremad R, Bahk KD, Shen YJ, et. al. Quantitative 19F NMR study of trifluorothymidine metabolism in rat brain. NMR Biomed. 1999;12:373–380.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Van Groeningen CJ, Laurensse EJ, et. al. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer. 1991;68:1903–1909.
   PubMed Web of Science ®Google Scholar
• Cleary JM, Mayer RJ, Cutsem E, et. al. Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): results from 3 phase 1 trials and the phase 3 RECOURSE trial. J Clin Oncol. 2015;33s(suppl):abstr 2579.
   Google Scholar
• Ansfield FJ, Ramirez G. Phase I and II studies of 2ʹ-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep. 1971;55:205–208.
   PubMedGoogle Scholar
• Kaufman HE, Heidelberger C. Therapeutic antiviral action of 5-trifluoromethyl-2ʹ-deoxyridine in herpes simprex keratitis. Science. 1964;145:585–586.
   PubMed Web of Science ®Google Scholar
• Carmine AA, Brogden RN, Heel RC, et. al. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs. 1982;23:329–353.
   PubMed Web of Science ®Google Scholar
• Hong DS, Abbruzzese JL, Bogaard K, et. al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006;107:1383–1390.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary G, Kopetz S, et. al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008;26:445–454.
   PubMed Web of Science ®Google Scholar
• Green MC, Pusztai L, Theriault LR, et. al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 24 18S (June 20 Supplement) 2006;24:Abstract 10576.
   Google Scholar
• Overman MJ, Kopetz S, Varadhachary G, et. al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008;26:794–799.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rosen LS, Mayer RJ, et. al. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015;76:925–932.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Mizunuma N, Yamazaki K, et. al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993–1001.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et. al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Kazuno H, Emura T, et. al. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17:277–283.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat Rev. 2015;41:777–783.
   PubMed Web of Science ®Google Scholar
• Salonga D, Danenberg KD, Johnson M, et. al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–1327.
   PubMed Web of Science ®Google Scholar
• Leichman CG, Lenz HJ, Leichman L, et. al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223–3229.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HH, Freemantle S, et. al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194–205.
   PubMed Web of Science ®Google Scholar
• Temmink OH, Hoebe EK, Van Der Born K, et. al. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer. 2007;96:231–240.
   PubMed Web of Science ®Google Scholar
• Nukatsuka M, Nakagawa F, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35:4605–4615.
   PubMed Web of Science ®Google Scholar
• Temmink OH, Hoebe EK, Fukushima M, et. al. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer. 2007;43:175–183.
   PubMed Web of Science ®Google Scholar
• Nukatsuka M, Nakagawa F, Saito H, et. al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35:1437–1445.
   PubMed Web of Science ®Google Scholar
• Bijnsdorp IV, Kruyt FA, Gokoel S, et. al. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci. 2008;99:2302–2308.
   PubMed Web of Science ®Google Scholar
• Tsukihara H, Nakagawa F, Sakamoto K, et. al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33:2135–2142.
   PubMed Web of Science ®Google Scholar
• Bijnsdorp IV, Kruyt FA, Fukushima M, et. al. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci. 2010;101:440–447.
   PubMed Web of Science ®Google Scholar
• Kuboki Y, Nishina T, Shinozaki E, et. al. An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE). J Clin Oncol. 2015;33(suppl):abstr 3544.
   Google Scholar
• Komatsu Y, Yoshino T, Mizunuma N, et. al. The value of thymidine kinase 1 (TK1) and thymidine phosphorylase (TP) expression as predictive factors with the treatment efficacy of TAS-102, a novel antitumor agent, in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer. 2011;47(suppl. 1):s421.
   Google Scholar
• Sakamoto K, Yokogawa T, Ueno H, et. al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2ʹ-deoxy-5-fluorouridine into DNA. Int J Oncol. 2015;46:2327–2334.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Komoto I, Oka H, et. al. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer Chemother Pharmacol. 2015;76:325–333.
   PubMed Web of Science ®Google Scholar